Harmony Biosciences Holdings, Inc. HRMY
Institutional shares held
45 Million
130K
calls
46.5K
puts
Total value of holdings
$1.56B
$4.5M
calls
$1.61M
puts
Market Cap
$2.05B
59,161,400
Shares Out.
Institutional ownership
76.03%
# of Institutions
280
We take great care to ensure that the data presented and summarized in this overview for Harmony Biosciences Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HRMY
View all-
Valor Management LLC Chicago, IL6.62MShares$230 Million91.68% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$203 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.7MShares$163 Million0.0% of portfolio
-
State Street Corp Boston, MA1.58MShares$54.8 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO1.29MShares$44.7 Million0.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.22MShares$42.5 Million0.01% of portfolio
-
Lsv Asset Management Chicago, IL1.19MShares$41.5 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA966KShares$33.5 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0888KShares$30.8 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il862KShares$29.9 Million0.01% of portfolio
Latest Institutional Activity in HRMY
Top Purchases
Top Sells
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Insider Transactions at HRMY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2025
|
Kumar Budur CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
8,869
-47.3%
|
$257,201
$29.86 P/Share
|
|
May 01
2025
|
Kumar Budur CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,750
+50.0%
|
-
|
|
Apr 01
2025
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,987
-94.7%
|
$223,584
$32.8 P/Share
|
|
Mar 29
2025
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
8,014
-53.43%
|
$264,462
$33.19 P/Share
|
|
Mar 29
2025
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
-
|
|
Mar 03
2025
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,869
-94.87%
|
$155,808
$32.92 P/Share
|
|
Mar 03
2025
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,869
+50.0%
|
$38,952
$8.22 P/Share
|
|
Jan 27
2025
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,775
-100.0%
|
$67,450
$38.05 P/Share
|
|
Jan 27
2025
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,629
-100.0%
|
$61,902
$38.02 P/Share
|
|
Jan 24
2025
|
Kumar Budur CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,151
-52.63%
|
$43,738
$38.01 P/Share
|
|
Jan 24
2025
|
Kumar Budur CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,187
+50.0%
|
-
|
|
Jan 24
2025
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,037
-53.44%
|
$77,406
$38.01 P/Share
|
|
Jan 24
2025
|
Sandip Kapadia CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,812
+50.0%
|
-
|
|
Jan 24
2025
|
Jeffrey M. Dayno PRESIDENT, CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,567
-43.5%
|
$173,546
$38.01 P/Share
|
|
Jan 24
2025
|
Jeffrey M. Dayno PRESIDENT, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,500
+50.0%
|
-
|
|
Jan 24
2025
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,058
-39.37%
|
$40,204
$38.01 P/Share
|
|
Jan 24
2025
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,812
+50.0%
|
$237,180
$15.35 P/Share
|
|
Jan 24
2025
|
Jeffrey Dierks CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
13,125
-80.48%
|
$485,625
$37.4 P/Share
|
|
Jan 24
2025
|
Andrew Serafin CHIEF STRATEGY OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
865
-34.6%
|
$32,870
$38.01 P/Share
|
|
Jan 24
2025
|
Andrew Serafin CHIEF STRATEGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
344K
Shares
From
5
Insiders
| Exercise of conversion of derivative security | 344K shares |
|---|
Sell / Disposition
9.5M
Shares
From
10
Insiders
| Payment of exercise price or tax liability | 82.3K shares |
|---|---|
| Open market or private sale | 9.42M shares |